6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bortezomib is a selective proteasome inhibitor which has shown significant activity in a variety of hematologic malignancies including multiple myeloma, mantle cell lymphoma and marginal zone lymphoma. Thus, this agent is worth studying in patients with Waldenström's macroglobulinemia (WM).

          Related collections

          Author and article information

          Journal
          Haematologica
          Haematologica
          1592-8721
          0390-6078
          Dec 2005
          : 90
          : 12
          Affiliations
          [1 ] Department of Clinical Therapeutics, Euroclinic Hospital, Athens, Greece. mdimop@med.uoa.gr
          Article
          16330439
          5472b13c-6020-4eeb-bfd0-0b9abe0fb601
          History

          Comments

          Comment on this article